According to GlobalData, Phase II drugs for Androgen-Sensitive Prostate Cancer does not have ... a second- or third-line treatment for patients with locally advanced or metastatic non-small cell lung ...

“Our study revealed that approximately 30% to 35% of nearly 16,000 men in the United Kingdom with high-risk localized or locally advanced prostate cancer did not receive potentially curative ...

Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Colorectal Cancer.

Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer ... active surveillance for ...

Sir Chris Hoy hailed the fundraising as a “huge step forward” in the fight to make change. "The huge sum Paddy Power are ...

EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first ...

Although prostate cancer screening has been embraced by ... treatment over antiandrogen monotherapy in the setting of locally advanced disease. This study reveals the importance of radiation ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced the creation of a new Theranostics ...

Telix Pharmaceuticals Limited  and the Brussels-based Oncidium foundation today announce that results for the NOBLE Registry of TLX599-CDx (99mTc-iPSMA) have been published in the European Journal of ...

Cilag’s Rybrevant in combo with Lazcluze for first-line treatment of patients with EGFR-mutated advanced NSCLC: Beerse, Belgium Tuesday, Dec ...